Covid-19 Impact on Pneumonia Market 2021-2025: Industry Insights and Growth by Top Key Company’s - GSK, Pfizer, Merck, Novartis, Sanofi, Eli Lilly

Overview of Global Pneumonia Market:

This report provides in-depth study of “Global Pneumonia Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Pneumonia Market report also provides an in-depth survey of key players in the market organization.

According to the market research study, Pneumonia is leading cause of death across the world with fatality rate of 4-10%. Hospital-acquired pneumonia is the most common form among the others and it has a huge impact on life style of patient population. Further, it is associated with a high mortality rate and requires immediate medical intervention. Because of this, there is a huge demand of pharmacological intervention ineffective management of the disease.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/279618 .

The most important key factors driving the growth of the Global Pneumonia Market are rapid growth in the incidence of pneumococcal disease, rising bacterial resistance of streptococcus bacteria, HIV associated pneumonia, increase in prevalence of pneumonia and government initiatives and growing prevalence of community-acquired pneumonia. According to the World Health Organization (WHO), pneumonia is responsible for majority of deaths in children worldwide. In 2015, 16% of children deaths under 5 years of age are due to pneumonia. Many antibiotics are currently available in the market to treat bacterial pneumonia conditions.

Regionally, North America is projected to dominate the over forecast period owing to high research activities on novel molecules and high deaths related to bacterial pneumonia conditions are attributing the growth of this market. APAC is expected to dominate the market due to increase in healthcare infrastructure and high prevalence of pneumonia in South Asia countries.

Global Key Vendors:

1 Pfizer

2 GlaxoSmithKline (GSK)

3 Merck

4 Novartis

5 Sanofi

6 Eli Lilly and More……………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Pneumonia Market Report 2021” @ https://www.businessindustryreports.com/buy-now/279618/single .

Product Type Segmentation

1 Drugs

2 Vaccines

3 Oxygen Therapy

Industry Segmentation

1 Hospitals

2 Ambulatory Surgical Centers

3 Others

Worldwide Medical Industry News:

Pfizer (March 26, 2021) - EMA Approves New Storage Option for Pfizer-Biontech Vaccine, Easing Distribution and Storage of Doses across European Union - Pfizer Inc. and BioNTech SE announced today that the European Medicines Agency (EMA) approved storage of COMIRNATY at -25°C to -15°C for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers. The new data is a testament to the companies’ ongoing commitment to developing this vaccine further and collecting data in order to support broader and more flexible vaccine distribution and inoculation.

With this approval, the COMIRNATY vials can be stored in all 27 European Union (EU) member states at these updated temperatures for a total of two weeks alternatively to the storage at ultra-low temperatures. It marks an important milestone in the vaccine roll-out, as it could allow storage in pharmacies to support vaccinations at local practices/doctors’ offices. By enabling more individuals to store and administer the vaccine, the approval will help broaden access, while limiting strain on larger vaccination centers.

“From the beginning our goal was to make our vaccine broadly available to people around the world. This approval by the EMA will enable us to access important additional channels to distribute and administer our vaccine,” said Ugur Sahin, CEO and Co-founder of BioNTech. “It comes at an important point in time, as governments now have more flexibility to move from inoculations in vaccination centers to a more decentralized vaccine roll-out through local doctors and general practitioners to accelerate our path out of the pandemic.”

“We appreciate the collaboration with the EMA and other regulatory agencies around the world as we work to ensure our vaccine can be shipped and stored under increasingly flexible conditions,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “This new storage option in Europe will help make the vaccine even more accessible to people across the continent, another important step as we continue our global fight against this virus.”

The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/279618 .

Major Points in Table of Contents:

Global Pneumonia Market Report 2021

1 Pneumonia Product Definition

2 Global Pneumonia Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Pneumonia Shipments

2.2 Global Manufacturer Pneumonia Business Revenue

2.3 Global Pneumonia Market Overview

2.4 COVID-19 Impact on Pneumonia Industry

3 Manufacturer Pneumonia Business Introduction

3.1 Pfizer Pneumonia Business Introduction

3.2 GlaxoSmithKline (GSK) Pneumonia Business Introduction

3.3 Merck Pneumonia Business Introduction

3.4 Novartis Pneumonia Business Introduction

3.5 Sanofi Pneumonia Business Introduction

3.6 Eli Lilly Pneumonia Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.